ICAAC 2006: Gastric acid-suppressive drugs linked to C difficile infection
The use of acid-suppressive drugs, particularly proton pump inhibitors (PPIs), was associated with an increase in the risk of community-acquired Clostridium difficile-associated disease (CDAD) in the United Kingdom, reported Sandra Dial, MD, MSc, at the 45th ICAAC meeting in Washington, DC.
The use of acid-suppressive drugs, particularly proton pump inhibitors (PPIs), was associated with an increase in the risk of community-acquired Clostridium difficile-associated disease (CDAD) in the United Kingdom, reported Sandra Dial, MD, MSc, at the 45th ICAAC meeting in Washington, DC.
Using the United Kingdom General Practice Research Database, she conducted 2 population-based case-control studies to evaluate the incidence of CDAD according to the use of gastric acid-suppressant drugs. In the first study, each case was matched to 10 controls randomly selected from the database. In the second study, community-acquired cases (cases not hospitalized in the previous year) were matched with controls also not hospitalized in the previous year.
Seventy-four percent (n=1,233) of the patients who developed CDAD had not been admitted to the hospital in the previous year, and less than 50% had taken antibiotics in the 3 months prior to developing CDAD.
After controlling for comorbidities and the use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin, current use of a PPI increased the risk of community-acquired CDAD by 2.9-fold. Current use of H2-receptor antagonists doubled the risk, and current use of an NSAID other than aspirin was associated with a 30% increased risk. Other factors associated with community-acquired CDAD were renal failure, inflammatory bowel disease, malignancy, and being positive for methicillin-resistant Staphylococcus aureus (MRSA).
The larger relative risk with current PPI versus H2-receptor antagonist use supports the hypothesis that greater suppression of gastric acid increases this risk, said Dr Dial, attending staff, department of critical care, McGill University Health Centre, Montreal, Quebec, Canada.
Meanwhile, deaths or colon surgeries related to infection with C difficile are becoming more common in the United States, said Wallace Alston, MD, University of Vermont, and Fletcher Allen Health Care, both in Burlington, Vt..
Historically, only 1% to 2% of cases of C difficile have been severe (toxic megacolon) or fatal. Recent reports from the United States and Canada, however, suggest an increase in the number of severe cases, said Dr Alston.
Outcomes were examined for 867 hospitalizations at Fletcher Allen Health Care that included a confirmed diagnosis of C difficile between January 1, 2000, and December 31, 2004.
One hundred thirty-two (15.2%) of the patients died. Compared with the baseline period (2000–2003), the case fatality rate "definitely" and "probably" due to C difficile increased from about 0.5% to greater than 3.0% (P<.01). The rate of definite death, probable death, or colectomy due to C difficile infection increased nearly 6-fold from the baseline period to 2004, from 1.4% to 8.2% (P<.001).
Findings from the study have since been published in the Journal of the American Medical Association (2005;294:2989–2995).
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
